{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:07:33Z","timestamp":1791403653200,"version":"4.3.3"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[1998,7,1]],"date-time":"1998-07-01T00:00:00Z","timestamp":899251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1998,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Honokiol, a neolignane derivative of Magnolia bark, has central depressant action and, at much lower doses, anxiolytic activity. We have investigated the characteristics of the behavioural effects of honokiol by means of an elevated plus-maze test.<\/jats:p><jats:p>In the plus-maze test a single oral dose of 20 mg kg\u22121 honokiol significantly prolonged the time spent in the open arms of the maze, suggesting anxiolytic effect. Moreover, when honokiol was administered daily for seven days and the plus-maze test was conducted 3 or 24 h after the last administration, significant prolongation of the time in the open arms was manifested even for doses of 0.2 mg kg\u22121. The maximum effect was observed for doses of 0.5 mg kg\u22121. Honokiol at any dose in both single and repeated administration schedules caused neither change in motor activity nor disruption of traction performance. Orally administered diazepam, 0.5\u20132 mg kg\u22121, caused dose-dependent prolongation of the time spent in the open arms of the maze with a significant increase in motor activity at 1 mg kg\u22121, and dose-dependent disruption of traction performance. The changes in the plus-maze performance after treatment for seven days with 0.2 mg kg\u22121 honokiol and after a single treatment with 1 mg kg\u22121 diazepam were almost equivalent. The effect of honokiol (0.2 mg kg\u22121, treatment for seven days) was inhibited by subcutaneous flumazenil (0.3 mg kg\u22121) and (+)-bicuculline (0.1 mg kg\u22121) and by intraperitoneal CCK-4 (50 \u03bcg kg\u22121) and caffeine (30 mg kg\u22121). The anxiolytic effect of diazepam (1 mg kg\u22121) was also inhibited by flumazenil and bicuculline. However, the combined administration of diazepam with caffeine enhanced the effect, and diazepam completely reversed the effect of CCK-4.<\/jats:p><jats:p>These results suggest that, in contrast with diazepam, honokiol selectively induces an anxiolytic effect with less liability of eliciting motor dysfunction and sedation or dis-inhibition. The combined effects of the drug also revealed that the mechanism of anxiolytic effect of honokiol is partially different from that of diazepam.<\/jats:p>","DOI":"10.1111\/j.2042-7158.1998.tb07146.x","type":"journal-article","created":{"date-parts":[[2011,4,13]],"date-time":"2011-04-13T15:01:16Z","timestamp":1302706876000},"page":"819-826","source":"Crossref","is-referenced-by-count":80,"title":["Behavioural Pharmacological Characteristics of Honokiol, an Anxiolytic Agent Present in Extracts of Magnolia Bark, Evaluated by an Elevated Plus-maze Test in Mice"],"prefix":"10.1093","volume":"50","author":[{"given":"Hisashi","family":"Kuribara","sequence":"first","affiliation":[{"name":"Department of Neurobiology and Behaviour, Behaviour Research Institute"},{"name":"Department of Pharmacology, The University of Texas Health Science Centre at San Antonio , 7703 Floyd Curl Drive, San Antonio, Texas 78284\u20137764,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B","family":"Stavinoha","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, The University of Texas Health Science Centre at San Antonio , 7703 Floyd Curl Drive, San Antonio, Texas 78284\u20137764,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Neuropsychopharmacology (Tsumura), Gunma University School of Medicine , 3\u201339-22 Showa-machi, Maebashi, Gunma 371\u20138511,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[1998,7,1]]},"reference":[{"key":"2024103110034969000_cit1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0091-3057(89)90230-X","article-title":"Caffeine-induced anxio-genesis: role of adenosine, benzodiazepine and noradrenergic receptors","volume":"32","author":"Baldwin","year":"1989","journal-title":"Pharmacol. Biochem. Behav."},{"key":"2024103110034969000_cit2","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/0028-3908(83)90120-X","article-title":"The neuropharmacology of various diazepam antagonists","volume":"22","author":"Boast","year":"1983","journal-title":"Neuropharmacology"},{"key":"2024103110034969000_cit3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1749-6632.1994.tb44075.x","article-title":"The cholecystokinin hypothesis of anxiety and panic disorder","volume":"713","author":"Bradwejn","year":"1994","journal-title":"Ann. NY Acad. Sci."},{"key":"2024103110034969000_cit4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archpsyc.1991.01810310021005","article-title":"Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings","volume":"48","author":"Bradwejn","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"key":"2024103110034969000_cit5","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/0006-3223(92)90179-4","article-title":"A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder","volume":"32","author":"Bradwejn","year":"1992","journal-title":"Biol. Psychiatry"},{"key":"2024103110034969000_cit6","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1176\/ajp.149.7.962","article-title":"Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings","volume":"149","author":"Bradwejn","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"2024103110034969000_cit7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archpsyc.1994.03950060050005","article-title":"The panicogenic effects of cholecystokinin tetrapeptide are antagonized by L-365, 260, a central cholecystokinin receptor antagonist, in patients with panic disorder","volume":"51","author":"Bradwejn","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"2024103110034969000_cit8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/archpsyc.1985.01790260027003","article-title":"Increased anxiogenic effects of caffeine in panic disorders","volume":"42","author":"Charney","year":"1985","journal-title":"Arch. Gen. Psychiatry"},{"key":"2024103110034969000_cit9","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0022-3565(25)24180-5","article-title":"Modification of the behavioral effects of chlordiazepoxide by methylxanthines and analogues of adenosine in squirrel monkeys","volume":"235","author":"Coffin","year":"1985","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024103110034969000_cit10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0196-9781(94)90104-X","article-title":"Biological action of cholecystokinin","volume":"15","author":"Crawley","year":"1994","journal-title":"Peptides"},{"key":"2024103110034969000_cit11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s002130050148","article-title":"GABAergic influences on plus-maze behaviour in mice","volume":"128","author":"Dalvi","year":"1996","journal-title":"Psychopharmacology"},{"key":"2024103110034969000_cit12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0165-6147(00)88973-7","article-title":"Use of the elevated plus-maze in the search for novel anxiolytic agents","volume":"16","author":"Dawson","year":"1995","journal-title":"Trends Pharmacol. Sci."},{"key":"2024103110034969000_cit13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1001\/archpsyc.1989.01810060031006","article-title":"Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers","volume":"46","author":"de Montigny","year":"1989","journal-title":"Preliminary findings. Arch. Gen Psychiatry"},{"key":"2024103110034969000_cit14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1248\/yakushi1947.93.4_422","article-title":"Studies on the components of Magnolia obovata THUNB. II. One the components of the methanol extract of the bark","volume":"93","author":"Fujita","year":"1973","journal-title":"Yakugaku Zasshi"},{"key":"2024103110034969000_cit15","first-page":"25","article-title":"The preclinical pharmacology of flumazenil","volume":"2","author":"Haefely","year":"1988","journal-title":"Eur. J. Anesthesiol."},{"key":"2024103110034969000_cit16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0014-2999(91)90156-K","article-title":"Evidence that CCKB receptor mediate the regulation of exploratory behaviour in the rat","volume":"193","author":"Harro","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"2024103110034969000_cit17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0166-4328(90)90121-T","article-title":"Rats with anxious or non-anxious type of exploratory behaviour differ in their brain CCK-8 and benzodiazepine receptor characteristics","volume":"39","author":"Harro","year":"1990","journal-title":"Behav. Brain Res."},{"key":"2024103110034969000_cit18","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1248\/cpb.32.5010","article-title":"Metabolism of magnolol from Magnoliae cortex. I. Application of liquid chromatography-mass spectrometry to the analysis of metabolites of magnolol in rats","volume":"32","author":"Hattori","year":"1984","journal-title":"Chem. Pharm. Bull."},{"key":"2024103110034969000_cit19","first-page":"157","article-title":"Metabolism of magnolol from Magnoliae cortex. II. Absorption, metabolism and excretion of [ring-14C]magnolol in rats","volume":"34","author":"Hattori","year":"1984","journal-title":"Chem. Pharm. Bull."},{"key":"2024103110034969000_cit20","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1111\/j.1476-5381.1995.tb16421.x","article-title":"Anxiolytic activity of adenosine receptor activation in mice","volume":"116","author":"Jain","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"2024103110034969000_cit21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF02246197","article-title":"Differential effects of flumazenil in alcoholic and nonalcoholic cirrhotic patients","volume":"120","author":"Kapczinski","year":"1995","journal-title":"Psychopharmacology"},{"key":"2024103110034969000_cit22","first-page":"219","article-title":"Animal behavioral models for testing antianxiety agents","volume":"18","author":"Kulkarni","year":"1996","journal-title":"Methods Find Exp. Clin. Pharmacol."},{"key":"2024103110034969000_cit23","first-page":"573","article-title":"Elevated plusmaze: a novel psychobehavioural tool to measure anxiety in rodents","volume":"13","author":"Kulkarni","year":"1991","journal-title":"Methods Find Exp. Clin. Pharmacol."},{"key":"2024103110034969000_cit24","first-page":"179","article-title":"The anxiolytic effect of oriental herbal medicines by an improved plus-maze test in mice: involvement of benzodiazepine receptors","volume":"18","author":"Kuribara","year":"1996","journal-title":"Jpn J. Neuropsychopharmacol."},{"key":"2024103110034969000_cit25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1254\/jjp.27.117","article-title":"Effects of central depressants on rota-rod and traction performances in mice","volume":"27","author":"Kuribara","year":"1977","journal-title":"Jpn J. Pharmacol."},{"key":"2024103110034969000_cit26","first-page":"643","article-title":"Investigation of the anxiolytic effect of the extracts derived from Saiboku-to, an oriental herbal medicine, by an improved plus-maze test in mice","volume":"18","author":"Kuribara","year":"1996","journal-title":"Jpn J. Neuropsychopharmacol."},{"key":"2024103110034969000_cit27","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/0028-3908(91)90021-3","article-title":"Effects of benzodiazepine receptor antagonist, flumazenil, on antinociceptive and behavioural responses to the elevated plus-maze in mice","volume":"30","author":"Lee","year":"1991","journal-title":"Neuropharmacology"},{"key":"2024103110034969000_cit28","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/BF00177912","article-title":"The use of a plus-maze to measure anxiety in the mouse","volume":"92","author":"Lister","year":"1987","journal-title":"Psychopharmacology"},{"key":"2024103110034969000_cit29","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1176\/ajp.149.5.691","article-title":"CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects","volume":"149","author":"Lydiard","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"2024103110034969000_cit30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1021\/np9702446","article-title":"Identification of magnolol and honokiol in the anxiolytic extracts of Saiboku-to, an oriental herbal medicine","volume":"61","author":"Maruyama","year":"1998","journal-title":"J. Nat. Prod."},{"key":"2024103110034969000_cit31","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1001\/archpsyc.1990.01810220033004","article-title":"Flumazenil provocation of panic attacks","volume":"47","author":"Nutt","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"key":"2024103110034969000_cit32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0091-3057(86)90552-6","article-title":"Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test for anxiety in the rat","volume":"24","author":"Pellow","year":"1986","journal-title":"Pharmacol. Biochem. Behav."},{"key":"2024103110034969000_cit33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0165-0270(85)90031-7","article-title":"Validation of open:close arm entries in an elevated plus-maze as a measure of anxiety in the rat","volume":"14","author":"Pellow","year":"1985","journal-title":"J. Neurosci. Methods"},{"key":"2024103110034969000_cit34","first-page":"497","article-title":"Adenosine and benzodiazepine action","volume-title":"The Pharmacology of Benzodiazepines","author":"Phillis","year":"1982"},{"key":"2024103110034969000_cit35","first-page":"1311","article-title":"Pharmacological challenges in anxiety disorders","volume-title":"Psychopharmacology: The Fourth Generation of Progress","author":"Price","year":"1995"},{"key":"2024103110034969000_cit36","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/BF00428424","article-title":"The effects of compounds related to gamma-aminobutylate and benzodiazepine receptors on behavioural responses to anxiogenic stimuli in the rat: punished bar pressing","volume":"85","author":"Quintero","year":"1985","journal-title":"Psychopharmacology"},{"key":"2024103110034969000_cit37","first-page":"1349","article-title":"Issues in the long-term treatment of anxiety disorders","volume-title":"Psychopharmacology: The Fourth Generation of Progress","author":"Schweizer","year":"1995"},{"key":"2024103110034969000_cit38","first-page":"1341","article-title":"The pharmacotherapy of acute anxiety","volume-title":"Psychopharmacology: The Fourth Generation of Progress","author":"Shader","year":"1995"},{"key":"2024103110034969000_cit39","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1073\/pnas.88.4.1130","article-title":"Evidence for an involvement of the brain cholecystokinin B receptor in anxiety","volume":"88","author":"Singh","year":"1991","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2024103110034969000_cit40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0378-4347(94)00031-X","article-title":"Pharmacokinetics of honokiol after intravenous administration in rats assessed using high-performance liquid chromatography","volume":"655","author":"Tsai","year":"1994","journal-title":"J. Chromatogr. B"},{"key":"2024103110034969000_cit41","first-page":"426","article-title":"Caffeine and behaviour: relation to psychopathology underlying mechanisms","volume":"20","author":"Uhde","year":"1984","journal-title":"Psychopharmacol. Bull."},{"key":"2024103110034969000_cit42","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/0278-5846(94)90090-6","article-title":"On the significance of cholecystokinin receptors in panic disorder","volume":"18","author":"Van Megen","year":"1994","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"2024103110034969000_cit43","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1254\/jjp.25.605","article-title":"Studies on the principles of Magnolia bark. Centrally acting muscle relaxant activity of magnolol and honokiol","volume":"25","author":"Watanabe","year":"1975","journal-title":"Jpn J. Pharmacol."},{"key":"2024103110034969000_cit44","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1248\/bpb1978.6.184","article-title":"Chemo-structural requirement for centrally acting muscle relaxant effect of magnolol and honokiol, ncolignane derivatives","volume":"6","author":"Watanabe","year":"1983","journal-title":"J. Pharm. Dyn."},{"key":"2024103110034969000_cit45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-2007-969825","article-title":"Pharmacological properties of magnolol and honokiol extracted from Magnolia officinalis: central depressant effects","volume":"49","author":"Watanabe","year":"1983","journal-title":"Plant Med."},{"key":"2024103110034969000_cit46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF02245824","article-title":"Current benzodiazepine issues","volume":"118","author":"Woods","year":"1995","journal-title":"Psychopharmacology"},{"key":"2024103110034969000_cit47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0165-1781(91)90124-8","article-title":"Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antago-nist flumazenil in panic disorder","volume":"36","author":"Woods","year":"1991","journal-title":"Psychiatry Res."},{"key":"2024103110034969000_cit48","first-page":"1777","article-title":"Abuse and therapeutic use of benzodiazepines and benzodiazepine-like drugs","volume-title":"Psychopharmacology: The Fourth Generation of Progress","author":"Woods","year":"1995"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.2042-7158.1998.tb07146.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/50\/7\/819\/60262272\/j.2042-7158.1998.tb07146.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/50\/7\/819\/60262272\/j.2042-7158.1998.tb07146.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T01:46:44Z","timestamp":1741139204000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/50\/7\/819\/6153092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,7,1]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[1998,7,1]]},"published-print":{"date-parts":[[1998,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.2042-7158.1998.tb07146.x","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"value":"2042-7158","type":"electronic"},{"value":"0022-3573","type":"print"}],"subject":[],"published-other":{"date-parts":[[1998,7]]},"published":{"date-parts":[[1998,7,1]]}}}